Stocks · News reference
Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 8:24 PM
- Checked
- Aug 12, 2026, 8:24 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share
Read original at benzinga8-K filing — Aligos Therapeutics, Inc. (ALGS)
Filed: 2026-08-06 AccNo: 0001171843-26-005294 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar